← Back to Search

[18F]FLOR PET/CT Imaging for Prostate Cancer

Phase 1
Waitlist Available
Led By Steven Rowe, M.D., Ph.D.
Research Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 10 days post-study drug dosing
Awards & highlights

Study Summary

This trial is testing how well a new imaging technique can detect prostate cancer that has spread to other parts of the body.

Who is the study for?
This trial is for men over 18 with confirmed adenocarcinoma of the prostate who have signs of recurring or spreading cancer. They must not have had cancer treatment in the last 2 weeks and should be able to follow study procedures. Men who've recently received radioisotopes or have conditions that may skew results can't participate.Check my eligibility
What is being tested?
[18F]FLOR (FC303) PET/CT imaging is being tested for its safety and ability to detect metastatic prostate cancer. Participants will receive an injection of [18F]FLOR, followed by a PET/CT scan to identify if their cancer has spread.See study design
What are the potential side effects?
While specific side effects are not listed, participants will be monitored for any adverse reactions following the injection of [18F]FLOR (FC303), which could range from mild allergic reactions to more serious complications.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 10 days post-study drug dosing
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 10 days post-study drug dosing for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of study drug emergent adverse events

Trial Design

1Treatment groups
Experimental Treatment
Group I: [18F]FLOR (FC303)Experimental Treatment1 Intervention
[18F]FLOR (FC303) PET/CT imaging.

Find a Location

Who is running the clinical trial?

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsLead Sponsor
554 Previous Clinical Trials
32,903 Total Patients Enrolled
57 Trials studying Prostate Cancer
3,378 Patients Enrolled for Prostate Cancer
FutureChemIndustry Sponsor
5 Previous Clinical Trials
563 Total Patients Enrolled
Steven Rowe, M.D., Ph.D.Principal InvestigatorJohns Hopkins University
1 Previous Clinical Trials
23 Total Patients Enrolled
1 Trials studying Prostate Cancer
23 Patients Enrolled for Prostate Cancer

Media Library

[18F]FLOR (FC303) Injection Clinical Trial Eligibility Overview. Trial Name: NCT04528199 — Phase 1
Prostate Cancer Research Study Groups: [18F]FLOR (FC303)
Prostate Cancer Clinical Trial 2023: [18F]FLOR (FC303) Injection Highlights & Side Effects. Trial Name: NCT04528199 — Phase 1
[18F]FLOR (FC303) Injection 2023 Treatment Timeline for Medical Study. Trial Name: NCT04528199 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many people have enrolled in this experimental research protocol?

"Correct. According to the information hosted on clinicaltrials.gov, this medical trial is actively searching for 10 volunteers, who can be found at 2 different sites. The study was initially posted on February 1st 2021 and most recently updated on December 14th 2021."

Answered by AI

Are there any current opportunities for enrolment in this trial?

"The clinical trial, initially posted on February 1st 2021 according to the data available at clinicaltrials.gov, is currently seeking participants. The details of this study have been most recently updated on December 14th 2021."

Answered by AI

How has [18F]FLOR (FC303) Injection been proven to be secure for patients?

"[18F]FLOR (FC303) Injection has been allocated a 1 on the safety scale by our Power team, signifying that there is limited data to demonstrate its efficacy and protectiveness."

Answered by AI
~2 spots leftby Mar 2025